Biotest successfully meets primary endpoint in phase III trial with Fibrinogen concentrate 14.02.2024 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS ...

Yimmugo, already approved for production and marketing in Europe, is the first U.S.-approved medicine in Biotest’s portfolio and is manufactured with an innovative process at Biotest’s new ...

Biotest, a Grifols Group company, is expected to launch its recently FDA-approved intravenous immunoglobulin in the U.S. in first quarter 2025 Yimmugo will be distributed by Kedrion in the U.S. as ...

Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin 12.09.2023 / 09:00 CET/CEST The issuer is solely responsible for the content of ...

- Having completed the Public Takeover Offer (PTO) and closed the acquisition of Tiancheng (Germany) Pharmaceutical Holdings, Grifols now controls 96.20% of the voting rights of Biotest AG and holds ...

DUBLIN--(BUSINESS WIRE)--The "Blood Plasma Market Share, Size, Trends, Industry Analysis Report, By Application, By Type, By End-Use, By Region, Segment Forecast, 2022 - 2030" report has been added to ...

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The ...

Market share in the global plasma-derived protein business is concentrated among a small number of global players, and Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 ...